Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation
Isabelle Amigues, Alexander H. Pearlman, Aarat Patel, Pankti Reid, Philip C. Robinson, Rashmi Sinha, Alfred H.J. Kim, Taryn Youngstein, Arundathi Jayatilleke, Maximilian F. Konig
Abstract
: Despite similarities, COVID-19-CSS appears to be distinct from HLH, MAS, and CRS, and the application of HLH diagnostic scores and criteria to COVID-19 is not supported by emerging data. While immunosuppressive therapy with glucocorticoids has shown a mortality benefit, cytokine inhibitors may hold promise as 'rescue therapies' in severe COVID-19. Given the arguably limited benefit in advanced disease, strategies to prevent the development of COVID-19-CSS are needed.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)CoronavirusInvestigational DrugsIntensive care medicineDiseaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakRescue therapyInternal medicineClinical trialPathologyInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19